Skip to main content Skip to main menu
UF Health University of Florida
Division of Hematology & Oncology Department of Medicine in the College of Medicine
Leighton A Elliott

Leighton A Elliott, MD

Assistant Professor

Department: MD-HEMATOLOGY-ONCOLOGY-ONCOL
Business Phone: (352) 273-7832
Business Email: leightonelliott@ufl.edu

On This Page

About Leighton A Elliott

I completed my residency training at Geisinger Medical Center in Danville, PA in a combined residency for both internal medicine and pediatrics where I was also Chief Resident. I then completed my specialty training in hematology and oncology at UF where I was also Chief Fellow. I chose to specialize in hematology and oncology due to the evolving landscape of immunotherapy and the need to improve care for the adolescent and young adult (AYA) population. I specialize in treating sarcomas – a rare cancer that affects the bones and soft tissues. As Director of the AYA Cancer Program, I work closely with our colleagues in Pediatric Oncology to optimize care for our AYA patients aged 15-45.

I aim to cure cancer using novel immunotherapies. As I believe we are close to this goal, I aim to decrease the morbidity and mortality of surgical interventions for cancer by developing therapies to work together with immunotherapy for advanced disease. We research various nanoparticles to accomplish this goal in my lab.

Outside of work, I enjoy spending time with my wife and our 7 children serving in church, playing board games, sports, and movie nights!

Board Certifications

  • Hematology
    ABIM
  • Internal Medicine
    ABIM
  • Pediatrics
    ABP

Clinical Profile

Specialties

  • Hematology

Subspecialties

  • Hematology and Oncology

Areas of Interest

  • Adult Soft Tissue Sarcoma
  • Ewing Sarcoma
  • Osteosarcoma
  • Rhabdomyosarcoma

Research Profile

Areas of Interest

  • Adolescents and Young Adults with Cancer
  • Cancer Immunotherapy
  • lipid nanoparticles

Publications

Academic Articles

Grants

  1. A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

    Active

    Role:
    Principal Investigator
    Funding:
    NRG ONCOLOGY FOU via NATL INST OF HLTH NCI

  2. A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High-Risk RetroPeritoneal Sarcoma (STRASS 2)

    Active

    Role:
    Principal Investigator
    Funding:
    NRG ONCOLOGY FOU via NATL INST OF HLTH NCI

  3. Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

    Active

    Role:
    Principal Investigator
    Funding:
    AVEO PHARMACEUTICALS

  4. RNA-nanoparticle (RNA-NP) vaccine for ARMS

    Active

    Role:
    Principal Investigator
    Funding:
    KATE AMATO FOUNDATION

  5. Novel RNA-Nanoparticle vaccine for treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy

    Active

    Role:
    Principal Investigator
    Funding:
    FL DEPT OF HLTH BIOMED RES PGM/J&E KING

Education

  1. MD

    Trinity School of Medicine

  2. MS Bioengineering

    Mercer University

  3. BS Biomedical Engineering

    Mercer University

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Business:
leightonelliott@ufl.edu
Addresses:
Business Mailing:
PO Box 100278
 GAINESVILLE FL 32610
Business Street:
1600 SW Archer Road
University of Florida Department of Medicine
 Gainesville FL 32610